Skip to content Skip to footer
Subscribe Now
4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress
EVENTS
4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress
Event description: Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-US Edition to be held on 28th June - 1st July 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers, and scientists from research institute pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC's,…
June 15, 20210Comments
Viewpoints_Dr. Stanley T. Crooke
VIEWPOINTS
PharmaShots Interview: n-Lorem Foundation’s Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients
In an interview with PharmaShots, Dr. Stanley T. Crooke, Founder, and Chief Executive Officer and Chairman of the Board at n-Lorem Foundation share his views on the collaboration with Ultragenyx. Shots: n-Lorem Foundation is the first & only foundation of its kind with a mission to provide life-saving treatments to patients who have diseases caused by extremely rare…
June 15, 20210Comments
Viewpoints_Dr. Maria Ines Mitrani
VIEWPOINTS
PharmaShots Interview: Organicell’s Dr. Maria Ines Mitrani Shares Insights on the Zofin for COVID-19
In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India. Shots: This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, which has entered into a product testing and distribution agreement with Organicell…
June 15, 20210Comments
Viewpoints_Dr. Malcolm Barratt-Johnson
VIEWPOINTS
PharmaShots Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies
In an interview with PharmaShots, Dr. Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs shared his views on the psychedelic therapies, the company's business model, and your plans for scaling the psychedelics therapies. Shots: Albert Labs will be the first psychedelics company to use an accelerated pathway, known as RWE studies, to swiftly provide access to patients…
June 11, 20210Comments
Viewpoints_Federico Grossi
VIEWPOINTS
PharmaShots Interview: Apellis’ Federico Grossi Shares Insights on the Data in GA Presented at ARVO 2021
In an interview with PharmaShots, Apellis' Chief Medical Officer, Federico Grossi shares his views on the data presented at ARVO 2021. The studies support AI analytics as a tool to distinctly measure disease activity well as the therapeutic effect in GA. Shots: Apellis presented five oral presentations from an AI collaboration with the Ophthalmic Imaging Analysis (OPTIMA)…
June 9, 20210Comments
Viewpoints_Mike Crichton
VIEWPOINTS
PharmaShots Interview: GSK’s Mike Crichton Shares Insights on the Approval of Benlysta in Europe
In an interview with PharmaShots, Mike Crichton, Senior Vice President, Global Therapy Area Head, Specialty & Primary Care at GSK shares his views on the European Commission's approval of Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN). Shots: The European Commission approved the expanded use of GSK's…
June 8, 20210Comments
Viewpoints_Dr. Gill Diamond and Joshua McClure
VIEWPOINTS
PharmaShots Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2
In an interview with PharmaShots, Dr. Gill Diamond, Scientific Advisory Board Member and Joshua McClure, CEO and Co-founder of Maxwell Biosciences share their views on the news findings of the company published in MDI that demonstrated that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2. Shots: The studies showed that antiviral peptoids…
June 7, 20210Comments
Viewpoints_Rich Colvin
VIEWPOINTS
PharmaShots Interview: bluebird bio’s Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy
In an interview with PharmaShots, Rich Colvin, M.D., Ph.D., Interim Chief Medical Officer at bluebird bio shares his views on the Skysona and its working on CALD patients. Shots: If granted marketing authorization, Skysona would be the first approved one-time gene therapy for CALD which is a rare neurogenerative disease with typically childhood onset The CHMP opinion…
June 4, 20210Comments